Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2450 + progestin
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (for TQB2450), Oral (for Most Progestins)
01
Overview
TQB2450 + progestin is an investigational combination therapy consisting of TQB2450, a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and a progestin, a class of synthetic hormones that mimic the effects of natural progesterone. TQB2450 (Benmelstobart) acts as an immune checkpoint inhibitor by blocking PD-L1, thereby enhancing anti-tumor immune responses. Progestins are commonly used in hormonal therapies for gynecological conditions and cancers due to their ability to modulate endometrial growth and hormone-driven tumor proliferation. This combination is being studied primarily for fertility-sparing treatment in patients with mismatch repair-deficient endometrial cancer (MMRd EC), aiming to improve therapeutic efficacy, reduce recurrence rates, and enhance tumor prognosis[2][6]. The developer of TQB2450 is Chia Tai Tianqing Pharmaceutical Group.
- Brand names
- Benmelstobart
02
Targets
PR (Progesterone receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on TQB2450 + progestin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2450 + progestin.